Rajadhyaksha Viraj Deodatta
International Oncology Medical Director, AstraZeneca, Horizon Place, Capability Green, Luton, United Kingdom.
Perspect Clin Res. 2020 Jul-Sep;11(3):124-127. doi: 10.4103/picr.PICR_164_20. Epub 2020 Jul 6.
The spread of coronavirus epidemic has resulted in a change in the work schedule for Medical affairs professionals in the pharmaceutical industry. There has been an increase in virtual scientific interactions and prioritization of scientific communication. In the long term, this is likely to affect the structure and responsibilities of Medical affairs teams. New areas such as interactions with patients' groups, leading treatment access in specific channels of health-care delivery and role in specialty care are likely to be an integral part of the Medical Affairs function. Along with that, Medical Affairs teams would take a proactive role in developing platforms for real-world evidence programs and forging cross-industry partnerships. To make this successful, Medical affairs teams will have to build specialized skills such as expertise in healthcare, use of digital technology, patient engagement, and soft skills such as agility and ability to influence. The future of medical affairs is set for a major change.
冠状病毒疫情的蔓延导致制药行业医学事务专业人员的工作安排发生了变化。虚拟科学互动有所增加，科学沟通也被列为优先事项。从长远来看，这可能会影响医学事务团队的结构和职责。与患者群体互动、在特定医疗保健提供渠道引领治疗可及性以及在专科护理中发挥作用等新领域，很可能会成为医学事务职能的一个组成部分。与此同时，医学事务团队将在开发真实世界证据项目平台以及建立跨行业伙伴关系方面发挥积极作用。为了实现这一目标，医学事务团队将必须培养专业技能，如医疗保健专业知识、数字技术应用、患者参与度，以及诸如灵活性和影响力等软技能。医学事务的未来将发生重大变革。
